3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
5
Neoplasms
2
Thrombosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Cyclophosphamide
53
fludarabine phosphate
50
Tacrolimus
41
Busulfan
41
Peripheral Blood Stem Cell Transplantation
37
Mycophenolic Acid
36
Whole-Body Irradiation
34
Antilymphocyte Serum
34
Cyclosporine
27
Methotrexate
25
fludarabine
24
Melphalan
20
Radiotherapy
19
Filgrastim
16
Methylprednisolone
14
Cord Blood Stem Cell Transplantation
12
Cytarabine
11
thymoglobulin
10
ruxolitinib
10
Specimen Handling
10
Biopsy
10
Cyclosporins
9
sargramostim
8
Sirolimus
8
Etoposide
8
Alemtuzumab
8
Thiotepa
7
Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
Azacitidine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Myeloproliferative Disorders
×
apixaban
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled